| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Mectra Labs is a Bloomfield, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Great Plains Orthotics & Prosthetics is a Ames, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Action Sport Physio sports medicine clinics are renowned for the excellent results in the treatment of their patients rehabilitation needs. With a network of clinics across the province, our 400 multidisciplinary health professionals are available and accessible to provide the very best of quality care.
MedData is a leading national provider of technology-enabled healthcare services designed to improve financial outcomes for hospitals by enhancing the patient experience and expanding their access to healthcare. The MedData suite of solutions includes a range of patient access & communications, revenue cycle management, and consulting & analytics services, including full service billing & coding, patient balances, eligibility & disability, third party liability and other complex A/R services, and mobile-first engagement and communication software for patients and providers. MedData has built this national presence by becoming experts at the state level. To date, we have handled billing for more than 200 million patients at our growing network of more than 2,000 hospital sites nationwide. For more than 36 years, MedData has solidified its leadership position by providing innovative solutions to the medical community and serving millions of patients across numerous medical specialties.